Ustekinumab (brand name Stelara®) is a human interleukin-12 and -23 antagonist and has been indicated for the treatments of moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis. This review aims to synthesize and interpret the literature evaluating the off-label uses of ustekinumab. We performed searches in PubMed and ClinicalTrials.gov for clinical trials, observational studies, case series, and case reports evaluating label uses of ustekinumab. Studies evaluated the efficacy of ustekinumab for the following conditions: other types of psoriasis (expect plaque psoriasis and psoriatic arthritis), pityriasis rubra pilaris, hidradenitis suppurativa, atopic dermatitis, pyoderma gangrenosum, et al. Based on the available literature, ustekinumab appears to be a potential treatment choice for many other diseases. However, more clinical trials data are needed to adequately assess the safety and efficacy of ustekinumab for the treatment of these conditions.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/dth.15910 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Considerations in Paediatric and Adolescent Inflammatory Bowel Disease.
J Crohns Colitis
October 2024
Department of Paediatric Gastroenterology, Erasmus MC - Sophia Children's Hospital, Rotterdam, The Netherlands.
The incidence of inflammatory bowel disease [IBD] is rising most rapidly among children and adolescents. Paediatric-onset IBD is associated with a more extensive and severe disease course compared to adult-onset IBD. At a young age, screening for underlying genetic and immunological disorders is important and may impact treatment management.
View Article and Find Full Text PDFRapid Remission With Upadacitinib in a Child With Refractory Crohn's Disease and Mutation: A Case Report.
Curr Ther Res Clin Exp
July 2024
Department of Gastroenterology, Chongqing General Hospital, Chongqing University, Chongqing, China.
Article Synopsis
- - Managing pediatric Crohn's disease (PCD) is complicated due to severe complications and the need for more biologic therapies, such as transitioning to off-label options.
- - Upadacitinib, while effective in adults with inflammatory bowel disease and children with atopic dermatitis, has limited research on its use for PCD.
- - A case report showcases successful remission in a child with Crohn's disease who was unresponsive to multiple treatment options, including infliximab and prednisone, and had a specific gene mutation.
Emerging Role of Biologic Drugs Targeting IL-17 and IL-23: Pityriasis Rubra Pilaris.
Life (Basel)
July 2024
Section of Dermatology-Department of Clinical Medicine and Surgery, University of Naples Federico II, 80131 Napoli, Italy.
Article Synopsis
- Pityriasis rubra pilaris (PRP) is a rare skin disease that causes red and scaly patches, making it hard to treat.
- Because PRP is uncommon and can sometimes get better on its own, studying how to treat it is tricky.
- New medicines that target specific parts of the immune system, like IL-17 and IL-23, have shown some promise for treating PRP, but more research is needed to understand how well they work.
Ustekinumab is an effective therapy for adult Crohn's disease (CD), but data in paediatric CD patients are scarce. The aim of the study was to describe the real-life effectiveness and safety of ustekinumab in paediatric CD. This is a multicentre review of children with Crohn's disease treated with ustekinumab.
View Article and Find Full Text PDFUstekinumab in pediatric patients with Crohn's disease: safety, and efficacy results from a multicenter retrospective study in China.
Front Pediatr
April 2024
Department of Gastroenterology, National Children's Medical Center, Children's Hospital of Fudan University, Shanghai, China.
Background: Ustekinumab (UST) is approved as an effective therapy for Crohn's disease (CD) in adults. Off-label use is increasing in the pediatric population, more data on safety and efficacy in pediatric patients with CD is urgently needed.
Aims: This study aimed to evaluate the clinical efficacy and safety of UST in children and adolescents with Crohn's disease.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!